The evaluation of biosimilars involves comparing them to their reference products in terms of quality, biological activity, and clinical outcomes. Regulatory agencies like the FDA and the EMA have stringent guidelines to assess biosimilars. This includes analytical studies, animal studies, and clinical trials to ensure that any differences do not impact safety or efficacy. Toxicological assessments are critical during these evaluations to identify any potential adverse effects.
